(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual revenue growth rate of 167.4% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Centessa Pharmaceuticals's revenue in 2024 is $6,853,000.On average, 3 Wall Street analysts forecast CNTA's revenue for 2026 to be $4,239,727,668, with the lowest CNTA revenue forecast at $1,895,780,565, and the highest CNTA revenue forecast at $5,516,821,750. On average, 2 Wall Street analysts forecast CNTA's revenue for 2027 to be $14,158,170,728, with the lowest CNTA revenue forecast at $10,060,676,755, and the highest CNTA revenue forecast at $18,255,664,700.
In 2028, CNTA is forecast to generate $23,020,192,575 in revenue, with the lowest revenue forecast at $18,556,582,250 and the highest revenue forecast at $27,483,802,900.